Literature DB >> 15241169

Results of giant cell tumor of bone treated with intralesional excision.

Paul Saiz1, Walter Virkus, Patricia Piasecki, Alexander Templeton, Susan Shott, Steven Gitelis.   

Abstract

Treatment of giant cell tumor of bone ranges from intralesional curettage to en bloc resection. We think that intralesional treatment can be done with low recurrence and complication rates and that these patients have good functional results. The results for 40 patients treated by one surgeon with one technique for giant cell tumor of bone between 1985-1999 were reviewed. All patients were treated with intralesional excision of the tumor with adjunctive cautery, phenol, and methylmethacrylate. All patients had been followed up for a minimum of 2 years with the mean followup of 76 months (range, 26-178 months). In addition, recent functional evaluations were done on 23 patients at a mean followup of 90 months (range, 28-175 months). The local recurrence rate was 12.5%. The nononcologic complication rate was 7.5%. Using the Musculoskeletal Tumor Society functional evaluation, 93% of the patients had excellent results. This long-term followup study on patients treated with intralesional excision and methacrylate showed a low recurrence rate similar to those cited in the literature. Additionally, the complication rate was low and the function results were excellent.

Entities:  

Mesh:

Year:  2004        PMID: 15241169     DOI: 10.1097/01.blo.0000128280.59965.e3

Source DB:  PubMed          Journal:  Clin Orthop Relat Res        ISSN: 0009-921X            Impact factor:   4.176


  42 in total

1.  Which treatment is the best for giant cell tumors of the distal radius? A meta-analysis.

Authors:  Yu-Peng Liu; Kang-Hua Li; Bu-Hua Sun
Journal:  Clin Orthop Relat Res       Date:  2012-07-07       Impact factor: 4.176

2.  Similar local control between phenol- and ethanol-treated giant cell tumors of bone.

Authors:  Wei-Hsin Lin; Tsung-Yu Lan; Chih-Yu Chen; Karl Wu; Rong-Sen Yang
Journal:  Clin Orthop Relat Res       Date:  2011-07-06       Impact factor: 4.176

3.  In-depth analysis of local recurrence of giant cell tumour of bone with soft tissue extension after intralesional curettage.

Authors:  Liang Chen; Xiao-Yi Ding; Chengs-Sheng Wang; Ming-Jue Si; Lian-Jun Du; Wei-Bin Zhang; Yong Lu
Journal:  Radiol Med       Date:  2014-03-07       Impact factor: 3.469

4.  Ethanol as a local adjuvant for giant cell tumor of bone.

Authors:  Kevin B Jones; Barry R DeYoung; Jose A Morcuende; Joseph A Buckwalter
Journal:  Iowa Orthop J       Date:  2006

5.  Giant cell tumor of bone: are we stratifying results appropriately?

Authors:  Thomas J Kremen; Nicholas M Bernthal; Mark A Eckardt; Jeffrey J Eckardt
Journal:  Clin Orthop Relat Res       Date:  2012-03       Impact factor: 4.176

6.  Multiple giant cell tumors of bone arising from multiple fatty tumors.

Authors:  Alireza Eajazi; Arvin Kheterpal; Susan Kattapuram; Gunnlaugur Petur Nielsen; Daniel Ira Rosenthal
Journal:  Skeletal Radiol       Date:  2016-10-22       Impact factor: 2.199

Review 7.  The clinical approach toward giant cell tumor of bone.

Authors:  Lizz van der Heijden; P D Sander Dijkstra; Michiel A J van de Sande; Judith R Kroep; Remi A Nout; Carla S P van Rijswijk; Judith V M G Bovée; Pancras C W Hogendoorn; Hans Gelderblom
Journal:  Oncologist       Date:  2014-04-09

Review 8.  Giant Cell Tumor of Bone - An Overview.

Authors:  Anshul Sobti; Pranshu Agrawal; Sanjay Agarwala; Manish Agarwal
Journal:  Arch Bone Jt Surg       Date:  2016-01

9.  Conservative treatment of Campanacci grade III proximal humerus giant cell tumors.

Authors:  Richard D Lackman; Eileen A Crawford; Joseph J King; Christian M Ogilvie
Journal:  Clin Orthop Relat Res       Date:  2008-11-06       Impact factor: 4.176

10.  Bone defects following curettage do not necessarily need augmentation.

Authors:  Martti Hirn; Uday de Silva; Sujith Sidharthan; Robert J Grimer; Adesegun Abudu; Roger M Tillman; Simon R Carter
Journal:  Acta Orthop       Date:  2009-02       Impact factor: 3.717

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.